CAMP4 Therapeutics Reports Q2 2026 Revenue Growth but Increased Net Loss

CAMP4 Therapeutics Corporation reported its financial results for the second quarter of 2026, revealing a research and collaboration revenue of $1.8 million, an increase from $1.5 million in the same period last year. For the six months ending June 30, 2026, total revenue reached $3.1 million, compared to $2.4 million for the first half of 2025. Despite this revenue growth, the company experienced a net loss of $33.5 million for the quarter, significantly higher than the $12.6 million loss reported in the prior year. The net loss for the first half of 2026 was $51.9 million, compared to $25.0 million for the same period in 2025.

Operating expenses for the second quarter totaled $15.2 million, up from $14.5 million in the previous year, driven primarily by increased research and development costs. R&D expenses rose to $10.8 million from $10.3 million, reflecting higher personnel-related costs and clinical expenses associated with the advancement of the company's lead product candidate, CMP-002. General and administrative expenses also increased to $4.3 million from $4.2 million, attributed to higher travel and personnel costs.

CAMP4 Therapeutics has made strategic advancements, including the initiation of a Phase 1/2 clinical trial for CMP-002, which targets SYNGAP1-related disorders. The company received regulatory clearance from Australia and Argentina to begin this trial, with plans to expand to additional regions. As of June 30, 2026, CAMP4 had approximately $86.4 million in cash and cash equivalents, which, along with the recent net proceeds of $46.9 million from a private placement, is expected to fund operations through the end of 2028.

The company’s total liabilities increased to $94.1 million as of June 30, 2026, up from $70.1 million at the end of 2025, largely due to a rise in the derivative tranche liability, which reached $71.9 million. This increase reflects the fair value adjustments related to the company's financing arrangements. CAMP4 continues to rely on external funding sources to support its operations, as it has not yet generated revenue from product sales. The company anticipates that its expenses will continue to rise as it progresses through clinical trials and seeks regulatory approvals for its product candidates.